Healthcare provider profile · identity verified

Grayson Smith, MD

Internal Medicine · SAN MARCOS, TX · NPI 1740224567

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	405	109
Meloxicam	Meloxicam	340	103
Lisinopril	Lisinopril	325	98
Amlodipine Besylate	Amlodipine Besylate	317	85
Atorvastatin Calcium	Atorvastatin Calcium	274	81
Rosuvastatin Calcium	Rosuvastatin Calcium	249	79
Omeprazole	Omeprazole	244	72
Losartan Potassium	Losartan Potassium	236	64
Metformin Hcl	Metformin Hcl	224	69
Pantoprazole Sodium	Pantoprazole Sodium	214	61
Metoprolol Succinate	Metoprolol Succinate	203	63
Prednisone	Prednisone	181	116
Hydrochlorothiazide	Hydrochlorothiazide	180	52
Pravastatin Sodium	Pravastatin Sodium	158	46
Sertraline Hcl	Sertraline Hcl	152	47
Albuterol Sulfate Hfa	Albuterol Sulfate	141	34
Glipizide	Glipizide	136	37
Lovastatin	Lovastatin	122	34
Tamsulosin Hcl	Tamsulosin Hcl	121	36
Azithromycin	Azithromycin	112	86
Furosemide	Furosemide	110	34
Gabapentin	Gabapentin	100	34
Montelukast Sodium	Montelukast Sodium	93	28
Allopurinol	Allopurinol	89	24
Trazodone Hcl	Trazodone Hcl	88	19
Fluticasone Propionate	Fluticasone Propionate	86	34
Simvastatin	Simvastatin	78	25
Famotidine	Famotidine	76	21
Doxazosin Mesylate	Doxazosin Mesylate	74	21
Metformin Hcl Er	Metformin Hcl	67	17
Pioglitazone Hcl	Pioglitazone Hcl	67	18
Carvedilol	Carvedilol	66	25
Tramadol Hcl	Tramadol Hcl	62	26
Valsartan	Valsartan	61	17
Potassium Chloride	Potassium Chloride	60	20
Citalopram Hbr	Citalopram Hydrobromide	57	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	55	15
Eliquis	Apixaban	51	15
Finasteride	Finasteride	50	14
Synthroid	Levothyroxine Sodium	50	15
Amoxicillin	Amoxicillin	49	37
Ezetimibe	Ezetimibe	46	14
Meclizine Hcl	Meclizine Hcl	45	23
Metoprolol Tartrate	Metoprolol Tartrate	45	12
Lorazepam	Lorazepam	44	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	44	14
Levofloxacin	Levofloxacin	42	35
Ozempic	Semaglutide	41	11
Clopidogrel	Clopidogrel Bisulfate	39	suppressed
Atenolol	Atenolol	38	suppressed
Cephalexin	Cephalexin	38	33
Duloxetine Hcl	Duloxetine Hcl	38	12
Escitalopram Oxalate	Escitalopram Oxalate	38	16
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	37	33
Bupropion Xl	Bupropion Hcl	37	suppressed
Celecoxib	Celecoxib	34	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	30	suppressed
Clonazepam	Clonazepam	29	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	29	suppressed
Januvia	Sitagliptin Phosphate	29	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	29	suppressed
Alendronate Sodium	Alendronate Sodium	28	suppressed
Nystatin	Nystatin	28	12
Alprazolam	Alprazolam	27	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	27	25
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	27	18
Fenofibrate	Fenofibrate	26	suppressed
Benazepril Hcl	Benazepril Hcl	25	suppressed
Rybelsus	Semaglutide	23	suppressed
Valacyclovir	Valacyclovir Hcl	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	22	suppressed
Pregabalin	Pregabalin	22	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Ondansetron Odt	Ondansetron	19	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	19	18
Buspirone Hcl	Buspirone Hcl	18	suppressed
Colchicine	Colchicine	18	14
Diclofenac Sodium	Diclofenac Sodium	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Testosterone	Testosterone	17	suppressed
Testosterone Cypionate	Testosterone Cypionate	17	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Fluconazole	Fluconazole	16	12
Irbesartan	Irbesartan	16	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Raloxifene Hcl	Raloxifene Hcl	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Enalapril Maleate	Enalapril Maleate	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Ramipril	Ramipril	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	14	suppressed
Eszopiclone	Eszopiclone	14	suppressed
Mounjaro	Tirzepatide	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Glipizide Er	Glipizide	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Aspirin-Dipyridamole Er	Aspirin/Dipyridamole	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Estradiol	Estradiol	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error